OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - MEDTRONIC Stock

Certificat

DE000SF25RA7

Delayed Deutsche Boerse AG 05:08:53 2024-05-23 EDT
4.95 EUR -1.98% Intraday chart for OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - MEDTRONIC
Current month-9.82%
1 month-9.98%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-23 4.95 -1.98%
24-05-22 5.05 -0.20%
24-05-21 5.06 -0.98%
24-05-20 5.11 +2.61%
24-05-17 4.98 -0.80%

Delayed Quote Deutsche Boerse AG

Last update May 23, 2024 at 05:08 am

More quotes

Static data

Product typeCertificat Turbo Stop Loss
Buy / SellPUT
Underlying MEDTRONIC PLC
IssuerLogo Issuer Société Générale Société Générale
WKN SF25RA
ISINDE000SF25RA7
Date issued 2021-08-02
Strike 140.2 $
Maturity Unlimited
Parity 10 : 1
Emission price 1.8
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 6.78
Lowest since issue 1.29

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
85.76 USD
Average target price
94.77 USD
Spread / Average Target
+10.51%
Consensus